Soriot’s Vision For AZ: A Focused Innovation-Driven Biopharma
This article was originally published in The Pink Sheet Daily
AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.
You may also be interested in...
The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.
European policymakers look at options such as greater information exchange between countries to strengthen price negotiation, joint procurement, and more collaborative HTA reviews to help hold down the high prices of certain medicines; Hospira expands its biosimilar infliximab into major markets.
The U.K. drug maker went on the offense against Pfizer’s hostile takeover attempt May 6, laying out to investors its long-term revenue guidance forecasting $45 billion in revenues by 2023. Growth will be driven by a pipeline with $23 billion in peak sales potential.